Based on the scoring system used to assess treatment response, therapeutic success occurred in 67% of Baytril ® Otic-treated infections compared to 14% with placebo (r-value 2 0.001) after 14 days of treatment. Assessment of effectiveness was based on continued resolution of clinical signs 3 to 4 days following administration of the last dose.Īt study conclusion, Baytril ® Otic was found to be a significantly more effective treatment for canine otitis externa than the placebo regimen. Treatments were administered twice daily for up to 14 days. Qualified cases were randomly assigned to either Baytril Otic treatment (n=113) or to a comparable placebo-based regimen (n=56). The presence of active disease was verified by aural cytology, microbial culture and otoscopy/clinical scoring. One hundred and sixty-nine dogs (n=169), with naturally occurring active otitis externa participated in the study. The effectiveness of Baytril ® Otic was evaluated in a controlled, double-blind, multi-site clinical trial. EFFECTIVENESS:ĭue to its combination of active ingredients, Baytril ® Otic provides antimicrobial therapy against bacteria and fungi (which includes yeast) commonly encountered in cases of canine otitis externa. INDICATIONS:īaytril ® Otic is indicated as a treatment for canine otitis externa complicated by bacterial and fungal organisms susceptible to enrofloxacin and/or silver sulfadiazine (see Microbiology section). Therefore, when using Baytril ® Otic as a treatment for canine otitis externa, interpret susceptibility data cautiously. Topical administration of Baytril ® Otic to an exudate and debris-free canal, however, will generally result in local antimicrobial concentrations that greatly exceed serum and tissue levels resulting from systemic therapy. MICs are used in conjunction with pharmacokinetics to predict the in vivo efficacy of systemically administered antimicrobials. Results of agar/broth-dilution assays are reported as a Minimal Inhibitory Concentration (MIC) which represents the lowest antimicrobial concentration, expressed in μg/mL, capable of inhibiting the growth of a pathogenic microorganism. In vitro assays, such as disk-diffusion and agar/broth-dilution, are used to determine the susceptibilities of microbes to antimicrobial therapies. Baytril ® Otic is effective when used as a treatment for canine otitis externa associated with one or more of the following organisms: Malassezia pachydermatis, coagulase-positive Staphylococcus spp.,Pseudomonas aeruginosa, Enterobacter spp., Proteus mirabilis, Streptococci spp., Aeromonas hydrophila, Aspergillus spp., Klebsiella pneumoniae, and Candida albicans. In clinical field trials, Baytril ® Otic demonstrated elimination or reduction of clinical signs associated with otitis externa and in vitro activity against cultured organisms. 5,6 SSD suppresses microbial growth through inhibition of DNA replication and modification of the cell membrane. 4 This compound has a wide spectrum of antimicrobial activity against Gram negative and Gram positive bacteria and is also an effective antimycotic. Silver sulfadiazine (SSD) is synthesized from silver nitrate and sodium sulfadiazine. 1 The ultimate outcome of the fluoroquinolone intervention is DNA fragmentation and bacterial cell death. It is believed that fluoroquinolones actively bind with bacterial DNA:ENZYME complexes and thereby inhibit the essential processes catalyzed by the enzymes (DNA supercoiling and chromosomal decatenation). Fluoroquinolones elicit their bactericidal activities through interactions with two intracellular enzymes, DNA gyrase (DNA topoisomerase II) and DNA topoisomerase IV, which are essential for bacterial DNA transcription, synthesis and replication. Enrofloxacin, a 4-fluoroquinolone compound, is bactericidal with activity against a broad spectrum of both Gram negative and Gram positive bacteria.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |